A Multilocus Model of the Genetic Architecture of Autoimmune Thyroid Disorder, with Clinical Implications  by Vieland, Veronica J. et al.
REPORT
A Multilocus Model of the Genetic Architecture
of Autoimmune Thyroid Disorder, with Clinical Implications
Veronica J. Vieland,1,2,3,* Yungui Huang,1 Christopher Bartlett,1,2 Terry F. Davies,4 and Yaron Tomer5
We report here a preliminary model of the genetic architecture of Autoimmune Thyroid Disorder (AITD). Using a ﬂexible class of math-
ematical modeling techniques, applied to an established set of data and supplemented with information both from candidate-gene and
genome-wide-association studies and from basic bioinformatics, we ﬁnd strong statistical support for a model in which AITD is the result
of ‘‘hits’’ along three distinct genetic pathways: affected individuals have (1) a genetic susceptibility to clinical AITD, along with (2) a sep-
arate predisposition to develop the autoantibodies characteristic of AITD, and they also have (3) a predisposition to develop high levels
of autoantibodies once they occur. Genes underlying each of these factors then appear to interact with one another to cause clinical
AITD. We also ﬁnd that a genetic variant in CTLA4 that increases risk for AITD in some people might actually protect against AITD
in others, depending on which additional risk variants an individual carries. Our data show that the use of statistical methods for the
incorporation of information frommultiple sources, combined with careful modeling of distinct intermediate phenotypes, can provide
insights into the genetic architecture of complex diseases. This model has several clinical implications, which we believe will prove
relevant to other complex diseases as well.Autoimmune thyroid disease (AITD [MIM 608173]) in-
cludes a number of conditions that share common cellular
and humoral immune responses targeted at the thyroid
gland. AITD includes Graves’ disease (GD [MIM 275000])
and Hashimoto’s thyroiditis (HT [MIM 140300]), both of
which are characterized by the inﬁltration of the thyroid
by T and B cells that are reactive with thyroid antigens and
the production of thyroid autoantibodies (TAB), with the
resultant clinical manifestations.1 Although some evidence
has been found that there might be genes speciﬁc to either
GD or HT,2,3 there is also considerable evidence of genes
common to both and, in fact, of genes common tomultiple
autoimmune diseases, such as AITD and Type I Diabetes.
Genes known to play a role in AITD include HLA,3,4
CTLA4 (MIM 123890), thyroglobulin (TG [MIM 188450]),3
THSR,1 and CD401 (MIM 109535). An additional class of
genes implicated in multiple autoimmune diseases is the
protein tyrosine phosphatases (PTP). Genome-wide associ-
ation studies (GWAS) have recently reported associations
between PTPN2 (MIM 176887) and both Type 1 Diabetes
and AITD;5,6 a different PTP gene, PTPN22 (MIM 600716)
has also been implicated in AITD as well as in other auto-
immune diseases.1,3
Among the genes known to be associated with AITD,
cytotoxic T lymphocyte antigen-4 (CTLA4) on 2q33 is one
of the most well-studied genes.3,7 Associations with several
CTLA4 SNPs have been established, with the most widely
replicated of these being association with the G allele of
the A49G SNP (rs57563726), which has been consistently
found in multiple studies involving over 15,000 individ-
uals in all.7 This allele has also been shown to alter T cell
phosphorylation patterns in a cohort of normal individ-The Amuals.8 This suggests a possible gene pathway involving
both CTLA4 and genes in the PTP superfamily. Note too
that KIAA0350, which was recently reported to be associ-
ated with AITD and Type 1 diabetes on the basis of
GWAS,5,6 contains an immunoreceptor tyrosine-based
inhibitory motif, as does CTLA4.
Given that HLA, the PTP superfamily, and CTLA4 have
all been implicated in other autoimmune disorders, as
well as in AITD, a picture is beginning to emerge of a path-
way that may serve as a background to development of
autoimmunity in general. As might be expected, each of
the known background genes appears to contribute only
a small risk of disease. In particular, CTLA4 is estimated
to confer a relative risk of just 1.3–1.7.7 It seems likely
that additional AITD-speciﬁc genes remain to be discov-
ered and virtually certain that AITD genetic architecture
involves gene-gene interactions.
An additional issue in the modeling of the genetic archi-
tecture of AITD is that little is known about the genetics of
TAB. High TAB levels are pathognomonic of AITD, and
elevated levels in clinically unaffected individuals are
used to predict AITD risk. Understanding of the genetic re-
lationship between TAB and AITD therefore seems crucial to
understanding the mechanisms underlying AITD develop-
ment. But all AITD patients initially have high TAB levels,
which are subsequently reduced with treatment. Hence,
parsing of the genetic regulation of TAB versus that of
AITD itself is difﬁcult, requiring both appropriate data
sets and also statistical methods that can be tailored to
this particular situation.
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pedigrees (N ¼ 102, comprising 742 individuals, of whom
540 were genotyped), ascertained for the presence of at
least two members with clinical AITD (GD or HT) and at
least four available ﬁrst-degree relatives from two genera-
tions (avg. number of AITD individuals per pedigree ¼
2.6). This study had institutional review board approval.
GD was diagnosed by (1) documented clinical and bio-
chemical hyperthyroidism requiring treatment, (2) a dif-
fuse goiter, (3) the presence of TSHR antibodies, and/or
(4) diffusely increased I-131 uptake in the thyroid gland.
HT was diagnosed by (1) documented clinical and bio-
chemical hypothyroidism requiring thyroid-hormone re-
placement and (2) the presence of autoantibodies to thy-
roid peroxidase (TPO). These families were previously
analyzed for linkage to AITD with the use of LOD scores,2
yielding evidence of linkage to 6p, 8q, and 10q, with max-
imum multipoint heterogeneity LOD scores of 2.0, 3.5,
and 4.1, respectively.
Here we go beyond the search for individual loci to the
modeling of more complex phenotypic relationships and
gene-gene interactions. Novel data utilized in the current
analyses include TAB as a quantitative trait. For purposes
of these analyses, TAB was taken to be the maximum read-
ing obtained from assays for antithyroglobulin (Tg) and
anti-TPO; in both cases antibodies were measured by
speciﬁc radioimmunoassay (Kronus). TAB was assayed in
all available unaffected relatives (N ¼ 222). In addition, for
these analyses all samples were genotyped at the associated
CTLA4 A49G SNP.
The previous 10 cM microsatellite genome scan was also
available for all families. In brief, these data were generated
as follows: DNA was extracted from whole blood through
use of the Puregene kit (Gentra Systems), and the Perkin El-
mer microsatellite panel (version 2.0, total of 400 markers)
were typed as reported elsewhere;2 an additional 36
markers were run in regions of interest prior to the current
analyses (including CTLA4 A49G). PCR products were gen-
erated with standard protocols followed and processed
with an ABI 310 genetic analyzer (Applied Biosystems). Al-
lele calling was done with Genotyper 2.0 software. Marker
data were cleaned for the presence of Mendelian inconsis-
tencies, andMerlin9 was run in regions of interest to detect
unlikely double recombinants; the repeating of analyses
with potential genotyping errors removed did not change
results reported here.
All analyses were conducted with the software package
KELVIN,10 which implements the PPL class of models for
measurement of the strength of genetic evidence.11,12 The
PPL is parameterized in terms of a general approximating
likelihood, and all parameters of the traitmodel are then in-
tegrated out, permitting the use of Bayes’ theorem for com-
putation of the posterior probability of the hypothesis of
interest. All results were based on multipoint analysis;
Hardy-Weinberg equilibrium has been assumed through-
out. The Rutgers combined genetic map was used.13–15
In modeling of the genotype-phenotype relationship,
deﬁnition of the phenotype is critically important. Because1350 The American Journal of Human Genetics 82, 1349–1356, Junewe were interested in the genetic relationship between
AITD and TAB, we considered three distinct models: (A)
AITD, which considers AITD alone as a dichotomous
(Y or N) trait, independent of TAB; (B) TAB, which treats
TAB (presence/absence) as an independent risk factor for
development of AITD; and (C) TAB/AITD, under which
TAB is an underlying risk factor for AITD, with clinical
AITD being a manifestation of high levels of TAB under
a classical quantitative-trait-threshold model. (We lack suf-
ﬁcient data in these particular pedigrees to search for TAB
alone as a quantitative trait.)
Accordingly, three basic models were utilized in the anal-
yses presented here. The ﬁrst is a simple dichotomous trait
model, with parameters a (the standard admixture parame-
ter of Smith,16 representing the proportion of ‘‘linked’’ ped-
igrees), p (the disease-allele frequency), and the penetrance
vector fi (i ¼ 1..3, representing the probability that an indi-
vidual with genotype i develops disease, for each of the
threepossible genotypes:DD,Dd, anddd). Aswith all forms
of thePPL, the trait parameters are integratedoutof theﬁnal
statistic; while the gene frequency is integrated over its full
range, anorderingconstraint is imposedon thepenetrances
such that f1R f2R f3. This model has been shown to repre-
sent a robust approximation for the mapping of complex
traits,17–19 and because the parameters are integrated out
of the underlying likelihoods, no speciﬁc assumptions re-
garding their values are required. This model was used for
AITD, with only AITD individuals considered ‘‘affected’’ re-
gardless of TAB status; and for TAB, with all individuals with
either AITD or TAB> 0.30 (the lower limit of laboratory pre-
cision) considered ‘‘affected’’ for TAB. (Recall that all AITD
individuals have elevated TAB.)
The second model is a variation on the quantitative-
trait-threshold model described in detail in20,21 (For addi-
tional details on the PPL method in general see 21). The
trait locus is parameterized in terms of a and p, as above,
but the trait distribution is parameterized as a mixture of
continuous probability density functions, one for each
trait genotype. In the case of TAB, which has a ﬂoor value
at 0.3 (Kronus units/ml), we use a mixture of c2s, which
gives an excellent empirical ﬁt to the overall data. In addi-
tion, in order to take full advantage of all of the (dichoto-
mous and quantitative) data in modeling of the AITD-TAB
relationship, we extend this basic quantitative-trait model
to include a threshold parameter t, such that any affected
individual is presumed to have an underlying TAB value
greater than t and, similarly, any unaffected individual is
presumed to have a value less than t. As in the case of
the dichotomous trait, all parameters of the trait model
are then integrated out: thus, in this case the integration
is over a, p, a vector of three c2 means (degrees of freedom),
and t. Again an ordering constraint is placed on the means.
For purposes of these analyses, individuals with AITD were
considered affected, whereas unaffected individuals with
TAB R 0.3 were assigned their quantitative TAB levels. (Re-
call that in AITD patients, levels of TAB are reduced by treat-
ment; thus, quantitative values in affected individuals are2008
not genetically useful phenotypes.) Unaffected individuals
with a measured TAB < 0.3 were coded as unaffected. This
model enables us to parse genetic contributions to AITD
and TAB through simultaneous analysis in the same set of
pedigrees.
The ﬁnal model used here is a simple variant of each of
the models just described, in which instead of using a sin-
gle ordered vector of penetrances (or means, in the case of
the quantitative-trait-threshold model), we parameterize
the model in terms of two separate penetrance (mean)
vectors, allowing the penetrance (mean) to differ between
individuals who are GG or GA at the A49G CTLA4 SNP and
individuals who are AA.10 This gives rise to the epistasis
PPL, or E-PPL. As previously, the additional parameters
are integrated out of the ﬁnal model. (While allowing the
Figure 1. Baseline PPLs for AITD, TAB, and
TAB/AITD
(A) Baseline PPLs for AITD.
(B) Baseline PPLs for TAB.
(C) Baseline PPLs for TAB/AITD.
The x axis represents the genome in Kosambi cM
units for chromosomes 1- X. The y axis shows
the PPL on the probability scale, representing
the probability of a gene for the given phenotype
at each position.
means to differ across CTLA4 genotype clas-
ses, we constrained the threshold to be the
same regardless of CTLA4 status.) In this
way we explicitly model two-locus epistasis,
in which the penetrance (mean) at any
given locus is allowed to depend upon the
genotype at CTLA4. A further extension of
this method would be to model three-locus
interactions; however, this is not feasible at
present for computational reasons.
The PPL is on the probability scale, and its
interpretation is therefore straightforward:
a PPL of, for instance, 40%means that there
is a 40% probability of a trait gene at the
given location on the basis of these data.
Forbiological reasons andon thebasis of ear-
lier calculations,22 the prior probability at
each location is set to 2%, so that PPLs >
2% indicate (some degree of) evidence in
favor of the location as the site of a trait
gene,whereas PPLs< 2% represent evidence
against the location. The PPL is ameasure of
statistical evidence, not a decision-making
procedure; therefore there are no ‘‘signiﬁ-
cance levels’’ associated with PPL values
and the PPL is not interpreted in terms of
its associated error probabilities.23–26 Never-
theless, it may assist readers to have some
sense of scale relative to more-familiar fre-
quentist test statistics. In a simulation of
10,000 replicates under the null hypothesis (no trait gene
at the location being tested), PPLs of 5%, 25%, and 80%
were associated with Type 1 error probabilities of 0.02,
0.0009, and 0.0001, respectively.17 Because all model
parameters are integrated out of the PPL, its scale remains
constant acrossmodels. Thus, these results apply to all anal-
yses conductedhere. (Bycontrast,maximized statisticsneed
to be ‘‘adjusted’’ for the number of parameters over which
they are maximized.) We note too that, again, because it is
ameasureofevidence rather thana testofhypothesis, amul-
tiple-testing correction is not applied to the PPL, just as one
would not ‘‘correct’’ a measure of the temperature made in
one location for readings taken at different locations.
Figure 1 shows results for the baseline genome scan.
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presence of a trait gene (PPL < 2%) for AITD (Figure 1A),
and 95% of the genome showed PPLs < 5%. Against this
very clean baseline, six peaks (on 5p14, 8q24, 10q11,
10q21, 10q26, and 12q23) stand out. The peak on chromo-
some 8q24 is within a few cM of the thyroglobulin gene
(TG), a region implicated in earlier linkage studies.1,3
TAB analysis greatly strengthened evidence of a gene on
6p22 and suggested a potential new locus on 18p11, in
the vicinity of PTPN26 (Figure 1B). Note too the small
but clearly visible peak on 2q33, which contains CTLA4.
Each of these loci lines up with an attractive immune can-
didate gene or region. Interestingly, none of the six large
peaks for AITD recur in Figure 1B, suggesting that genes
that cause susceptibility to TAB in AITD patients can be dif-
ferent from genes that increase risk of AITD in the presence
of TAB.
Figure 2. Locations of CTLA4 Interactors,
Detected by Epistasis Analysis, for AITD, TAB,
and TAB/AITD
(A) Locations of CTLA4 interactors for AITD.
(B) Locations of CTLA4 interactors for TAB.
(C) Locations of CTLA4 interactors for TAB/AITD.
The x axis represents the genome in Kosambi cM
units for chromosomes 1- X. The y axis shows E-
PPL (epistasis) minus baseline PPL (no epistasis)
at each position; thus, the scale of the y axis dif-
fers from that of Figure 1. Because the E-PPL in-
volves integration over the full parameter space,
including both ‘‘epistasis’’ and ‘‘no epistasis’’
models, this difference will be> 0 in the presence
of evidence supporting epistasis and < 0 in the
presence of evidence against epistasis, with the
magnitude of the difference (positive or nega-
tive) indicating the relative strength of evidence
for or against interaction with CTLA4. Note that
PPL differences have been set to equal 0 (no evi-
dence for or against epistasis) over the region
containing CTLA4 itself.
TAB/AITD analysis revealed two new
peaks (Figure 1C) on 4q32 and 10p12 and
produced a substantially higher PPL over
the original AITD peak on 8q24. Again, it
appears that genes that regulate quantita-
tive levels of TAB can be distinct from both
genes conferring susceptibility to AITD
and genes determining susceptibility to
the presence or absence of TAB.
We then rescanned the genome for epi-
static interactions involving CTLA4. Inter-
estingly, this analysis did not detect any
loci unseen in baseline analyses. However,
three of the loci detected at baseline show
substantial evidence of interaction with
CTLA4 (10q21, 10q26 under the AITD
model, and 8q24 under the TAB/AITD
model), indicating that genetic effects at
these loci are subject to modiﬁcation by the CTLA4 geno-
type (Figure 2).
Along with PPLs, KELVIN also reports the maximizing
(maximum likelihood) trait model. Caveats apply when
one interprets the numerical values of parameters esti-
mated in this way (including the fact that consideration
of only the point estimates themselves might obscure
dimensions in which the surface is essentially ﬂat, as well
as more arcane issues27). However, all other things being
equal, this constitutes a statistically rigorous (approximat-
ing) procedure for estimation of trait parameters.28–31 We
took advantage of this feature to examine the epistasis
results in more detail.
We had anticipated that epistasis at the interacting loci
(8q24, 10q21, and 10q26) would conﬁrmG as the risk-con-
ferring allele, consistent with the association data from our1352 The American Journal of Human Genetics 82, 1349–1356, June 2008
group and others. This would manifest itself as increased
genotypic relative risk (in the case of the dichotomous
ATID model) among carriers of both the G allele and the
high-risk genotype(s) at an interacting locus or as corre-
sponding increases in the differences between genotypic
means (in the case of the quantitative TAB/AITD model).
Table 1 shows effect-size estimates for each of these loci.
On 8q24 and 10q26, AA individuals have no increase or
only a very slight increase in estimated risk even when
they carry the high-risk 8q24 genotypes or the high risk
10q26 genotypes. By contrast, the combination of the D
allele and the G CTLA4 allele produces dramatic pheno-
typic effects at both loci. (Note that when the penetrance
for dd individuals is estimated to be 0, the genotypic
relative risk is undeﬁned, or effectively inﬁnite.) Thus, for
these two loci, the G allele does appear to be the risk-
conferring allele.
However, on 10q21, carriers of the CTLA4 G allele and
the DD risk genotype have atmost a verymodest estimated
increase in risk, while CTLA4 AA homozygous individuals
with the high risk 10q21 genotype are the ones at greatly
increased risk of disease. Thus, notably, on 10q21 it is actu-
ally the AA CTLA4 genotype that increases risk.
It is also of interest to note the estimated threshold
values under the TAB/AITD model: these are 23, 0.3, 23,
and 8, on 3q27, 4q32, 8q24, and 10p12, respectively. The
Table 1. Effect of CTLA4 Genotypes on Relative Risks at
Interacting Loci
Genotype at CTLA4: GG/GA Genotype at CTLA4: AA
Locus
Genotype at
Locus: DD
Genotype at
Locus: Dd
Genotype at
Locus: DD
Genotype at
Locus: Dd
8q24 15* 5* 0 0
10q21 4 1 N* 1
10q26 N* N* 2 2
For the AITD model (10q21 and 10q26), the effect size is estimated as the
ratio of the penetrance for DD or Dd individuals, respectively, to the pene-
trance in dd individuals, where DD etc. are the unobserved disease geno-
types at the locus in question. A risk ratio of N indicates that the
estimated penetrance for the dd genotype was 0. For the TAB/AITD model
(8q24), the effect size is estimated as the corresponding differences in
genotypic means. These quantities are therefore not directly comparable
between row 1 (differences in mean) and rows 2 and 3 (relative risks) of
the table.
* High-risk two-locus genotype.The Amcommon clinical rule of thumb is that TAB R 3 (Kronus
units) represents a change in level of risk for AITD. How-
ever, if the threshold actually depends upon the speciﬁc
combination of genes involved for any particular individ-
ual with AITD, then it should be possible to modify this
rule on the basis of more speciﬁc knowledge of genetic
architecture. This could illustrate a realistic type of applica-
tion of personalized genomic medicine for many complex
disorders.
In view of the known involvement of some PTP family
genes in AITD, we also investigated whether any addi-
tional PTP genes localized to our PPL peaks. We conducted
a GO-term search based on two Biomart builds because the
annotations between these databases are not synchro-
nized. From a list of GO terms associated with both
PTPN2 and PTPN22, we searched for ‘‘protein tyrosine
phosphatase’’ (GO: 4725) and ‘‘phosphoric monoester hy-
drolase activity’’ (GO:16791). Between the two databases,
a total of 246 unique genes were identiﬁed; however, after
restriction of the list to independently annotated genes
common to both databases, just 120 genes remain. Figure 3
shows the locations of these genes superimposed on a sum-
mary PPL plot. We also include PLD1 (3q27) and GPLD1
(6p22) (which each appear in one of the two databases),
because the activity of CTLA4 has been demonstrated to
be dependent on phospholipase D activity.32
Intriguingly, several of the PPL peaks coincide with
genes from the PTP superfamily. Although this is far from
conclusive, we view these PTP genes as prime candidate
genes for additional study.
Table 2 contains a summary of salient results. Here, we
list all loci with PPL > 25% (corresponding in some sense
to p values < 0.0009). We have also included 2q33 and
18p11, which were picked up under the TAB model. From
a biological perspective, given the model under which we
detect them, these peaks might be anticipated to contain
genes relating to general immune response and therefore
to be relatively nonspeciﬁc to AITD. This would tend to
make effect sizes in the AITD sample (and, perhaps, in gen-
eral) relatively small and more difﬁcult to detect. Indeed,
there is strong prima facie support for this conjecture on
2q33 (over CTLA4), if not also on 18p11.6
Assembling these results into a unifyingmodel (Figure 4),
we begin to see an outline of the CTLA4-related genetic
architecture of AITD as a complex interplay amongFigure 3. All Detected PTP-Related
Genes, Shown as Individual Dots, Super-
imposed on a Summary PPL Graph
For summary purposes, each chromosome is
plotted under the phenotypic model that
maximizes the PPL on that chromosome;
for chromosome 10, because there are
multiple peaks maximizing under different
phenotypic models, the plot is based on
the models that maximize the PPL within
each of four segments of the chromosome.erican Journal of Human Genetics 82, 1349–1356, June 2008 1353
Table 2. Summary of Salient Results
Chromosome Position (cM) PPL (%)* Phenotypic Model Closest PTP-Related Gene**
2q33 218 8 TAB CTLA4 at 215 cM
3q27 190 32 Epistasis TAB/AITD PLD1 at 187.7 cM
5p14 47 28 AITD —
4q32 172 44 TAB/AITD —
6p22 50 38 TAB GPLD1 at 50 cM
8q24 132 90 Epistasis TAB/AITD —
10p12 44 69 TAB/AITD PTPLA at 42.4 cM
10q11 69 52 AITD PTPN20B at 67 cM
10q21 82 98 Epistasis AITD KIAA1274 at 88.9 cM
10q26 156 86 Epistasis AITD PTPRE at 159.8 cM
12q23 113 28 AITD —
18p11 36 14 TAB PTPRM at 29.6 cM; IMPA2 at 42.6 cM***
* The PPL is on the probability scale and has a direct interpretation as the probability of a gene for the specified phenotype at a particular location given
the data at hand. Note also that PPLs reported here for the epistasis models are the actual E-PPLs rather than the differences (E-PPL  PPL) plotted in
Figure 2.
** Also of potential interest from the GO-term search are MTMR6, which is visible in Figure 3 over the small peak on chromosome 13 (at 14 cM); and DUSP6,
near a secondary peak of 24% on chromosome 12 at 102 cM.
*** An association to PTPN2, also in 18p11, has been found with both Type 1 diabetes and AITD.5multiple genes, with distinct genes for each of the three
phenotypic models. Thus, clinical AITD appears to be the
result of ‘‘hits’’ along (at least) three separate genetic paths:
a genetic susceptibility to AITD; a predisposition to develop
the autoantibodies characteristic of AITD; and a propensity
to develop high levels of TAB once disease development be-
gins. Superimposed upon this collection of genes are inter-
actions across phenotypic categories. For instance, CTLA4
itself appears to regulate propensity to develop TAB (Y or
N), while interacting with both genes that predispose one
to AITD and genes that regulate quantitative levels of TAB.
Perhaps of most immediate relevance to other complex
disorders is the ﬁnding that it is not only the associated
CTLA4 G allele that is risk-conferring but, against certain
speciﬁc genetic backgrounds, it can apparently be the A al-
lele that is deleterious. The consistent associationwith G in
population studies is, then, presumably due to the higher
prevalence of those interacting factors for which G rather
than A is the deleterious variant (or, possibly, in strong dis-1354 The American Journal of Human Genetics 82, 1349–1356, Juneequilibriumwith a separate deleterious variant), but the rel-
ative prevalence of interacting factors is a matter of popula-
tionhistory andstructure rather thanofunderlyingbiology.
Thus, evenwithin the same gene, different alleles at a single
SNPmight be associated with risk in different subsets of pa-
tients. These ﬁndings are relevant to thewealth of newasso-
ciationsbeingdetectedbygenome-wide associationstudies.
Identiﬁcation of these subsets will be essential for the de-
sign of targeted treatments based on the immunogenetic
mechanisms causing disease. Therapies targeted to alter-
ation of the disregulated immunological pathways associ-
ated with the G allele would be beneﬁcial in some patients,
but they could be harmful or ineffective in those patients
whose disease is associated with the A allele. Indeed,
genetic background is emerging as a signiﬁcant factor af-
fecting efﬁcacy of therapeutic modalities in several condi-
tions, such as hypertension.33 These ﬁndings not only sug-
gest a new line of research into the role of CTLA4 in
autoimmune disease but, also, suggest that associationsFigure 4. Preliminary Model of CTLA4
Mediation of the Genetic Architecture
of AITD2008
based on aggregate data at the population level should be
interpreted with care before being merged into clinical
practice. This also illustrates that differences in population
history can change which of the two SNP alleles is the as-
sociated allele at a true disease locus, a possibility to keep
in mind when interpreting replication studies.
It is still unclear whether the other known AITD-related
genes (TSHR, CD40, and HLA itself) form a part of the same
pathway diagrammed in Figure 4 or whether they partici-
pate in independent pathways leading to the AITD pheno-
type under an expanded ‘‘locus heterogeneity’’ model in
which each component of the model is actually a separate
network of genes rather than an independently operating
single locus. Full exploration of this possibility will require
the modeling of interactions among more than two loci at
a time. In principle this requires only a trivial extension of
the current PPL framework. However, at present it remains
a challenge on purely computational grounds. This will be
a major focus of our further computational developments.
It also remains to be seen whether typical human data sets
will carry enough information on higher-order interac-
tions to be useful or whether the search for genetic archi-
tecture at that level of complexity will require recourse to
model organisms.
Even though the particulars of our proposed model
await molecular conﬁrmation, it seems clear to us from
the present study that considerable information regarding
complex genetic architecture can be recovered from hu-
man data sets under the right circumstances. These circum-
stances will include measurement and modeling of sets of
related phenotypes; incorporation of allelic associations
and linkage information into uniﬁed analyses; and, as
bioinformatics resources continue to develop, supplemen-
tation of statistical modeling with bioinformatically ob-
tained information about gene networks and pathways.
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